Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

5-S-cysteinyldopamine neurotoxicity: Influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease.

Aureli C, Cassano T, Masci A, Francioso A, Martire S, Cocciolo A, Chichiarelli S, Romano A, Gaetani S, Mancini P, Fontana M, d'Erme M, Mosca L.

J Neurosci Res. 2014 Mar;92(3):347-58. doi: 10.1002/jnr.23318. Epub 2013 Nov 22.

PMID:
24273027
2.

Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.

Lehmensiek V, Tan EM, Liebau S, Lenk T, Zettlmeisl H, Schwarz J, Storch A.

Neurochem Int. 2006 Apr;48(5):329-40. Epub 2006 Jan 6.

PMID:
16406146
3.

Specific pesticide-dependent increases in α-synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines.

Chorfa A, Bétemps D, Morignat E, Lazizzera C, Hogeveen K, Andrieu T, Baron T.

Toxicol Sci. 2013 Jun;133(2):289-97. doi: 10.1093/toxsci/kft076. Epub 2013 Mar 27.

PMID:
23535362
4.

alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.

Bazzu G, Calia G, Puggioni G, Spissu Y, Rocchitta G, Debetto P, Grigoletto J, Zusso M, Migheli R, Serra PA, Desole MS, Miele E.

CNS Neurol Disord Drug Targets. 2010 Aug;9(4):482-90. Review.

PMID:
20522009
6.

A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.

Myöhänen TT, Hannula MJ, Van Elzen R, Gerard M, Van Der Veken P, García-Horsman JA, Baekelandt V, Männistö PT, Lambeir AM.

Br J Pharmacol. 2012 Jun;166(3):1097-113. doi: 10.1111/j.1476-5381.2012.01846.x.

7.

Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.

Perfeito R, Cunha-Oliveira T, Rego AC.

Free Radic Biol Med. 2013 Sep;62:186-201. doi: 10.1016/j.freeradbiomed.2013.05.042. Epub 2013 Jun 3. Review.

PMID:
23743292
8.

Generation of a alpha-synuclein-based rat model of Parkinson's disease.

Recchia A, Rota D, Debetto P, Peroni D, Guidolin D, Negro A, Skaper SD, Giusti P.

Neurobiol Dis. 2008 Apr;30(1):8-18. doi: 10.1016/j.nbd.2007.11.002. Epub 2007 Nov 13.

PMID:
18313315
9.

Neuroprotection of α-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K.

Choong CJ, Say YH.

Neurotoxicology. 2011 Dec;32(6):857-63. doi: 10.1016/j.neuro.2011.05.012. Epub 2011 May 30.

PMID:
21658409
10.

Modulation of alpha-synuclein aggregation by dopamine: a review.

Leong SL, Cappai R, Barnham KJ, Pham CL.

Neurochem Res. 2009 Oct;34(10):1838-46. doi: 10.1007/s11064-009-9986-8. Epub 2009 May 15. Review.

PMID:
19444607
11.

Methylparaben protects 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and improved behavioral impairments in mouse model of Parkinson's disease.

Kopalli SR, Noh SJ, Koppula S, Suh YH.

Neurotoxicology. 2013 Jan;34:25-32. doi: 10.1016/j.neuro.2012.10.003. Epub 2012 Oct 12.

PMID:
23068419
12.

Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease.

Locke CJ, Fox SA, Caldwell GA, Caldwell KA.

Neurosci Lett. 2008 Jul 11;439(2):129-33. doi: 10.1016/j.neulet.2008.05.003. Epub 2008 May 7.

PMID:
18514411
14.

A newly discovered neurotoxin ADTIQ associated with hyperglycemia and Parkinson's disease.

Xie B, Lin F, Ullah K, Peng L, Ding W, Dai R, Qing H, Deng Y.

Biochem Biophys Res Commun. 2015 Apr 10;459(3):361-6. doi: 10.1016/j.bbrc.2015.02.069. Epub 2015 Mar 3.

PMID:
25744031
15.

Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.

Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Höglinger GU, Oertel WH, Hartmann A.

Exp Neurol. 2008 Mar;210(1):182-93. Epub 2007 Nov 1.

PMID:
18053987
16.

Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology.

Gerard M, Deleersnijder A, Daniëls V, Schreurs S, Munck S, Reumers V, Pottel H, Engelborghs Y, Van den Haute C, Taymans JM, Debyser Z, Baekelandt V.

J Neurosci. 2010 Feb 17;30(7):2454-63. doi: 10.1523/JNEUROSCI.5983-09.2010.

17.

Protective and toxic roles of dopamine in Parkinson's disease.

Segura-Aguilar J, Paris I, Muñoz P, Ferrari E, Zecca L, Zucca FA.

J Neurochem. 2014 Jun;129(6):898-915. doi: 10.1111/jnc.12686. Epub 2014 Mar 18. Review.

18.

Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.

Bellucci A, Collo G, Sarnico I, Battistin L, Missale C, Spano P.

J Neurochem. 2008 Jul;106(2):560-77. doi: 10.1111/j.1471-4159.2008.05406.x. Epub 2008 Apr 10.

19.

Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.

Mazzulli JR, Mishizen AJ, Giasson BI, Lynch DR, Thomas SA, Nakashima A, Nagatsu T, Ota A, Ischiropoulos H.

J Neurosci. 2006 Sep 27;26(39):10068-78.

20.

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

Olanow CW, Brundin P.

Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Review.

PMID:
23390095

Supplemental Content

Support Center